The ERK MAP kinase pathway plays a pivotal role in growth factor‐induced gene expression. However, genes whose expression is induced by the ERK pathway are not fully defined.

We have identified SGK (serum‐ and glucocorticoid‐inducible kinase) as an ERK‐inducible gene by the subtractive screening of Raf‐inducible genes. SGK is known to be similar in primary structure to AKT/PKB, PKC and PKA. Treatment of quiescent NIH‐3T3 cells with FGF, PDGF or TPA, which induced the sustained activation of ERKs, resulted in the strong induction of SGK, whereas treatment with EGF, which induced the transient activation of ERKs, did not induce a strong expression of SGK. The induction of SGK was blocked by pre‐treatment with a specific MEK inhibitor U0126, and expression of constitutively active MEK was able to induce SGK. Treatment with cycloheximide or vanadate prolonged the increased expression of SGK by FGF, concomitant with a more prolonged activation of ERKs.

Growth factor‐induced activation of the ERK MAP kinase pathway is necessary and sufficient for the induction of SGK.